PUBLISHER: The Business Research Company | PRODUCT CODE: 1946999
PUBLISHER: The Business Research Company | PRODUCT CODE: 1946999
The portable transcranial stimulation device is a compact and mobile unit designed to deliver targeted electrical or magnetic stimulation to the brain to influence neural activity. It improves cognitive and neurological functions through precise, non-invasive treatment. Its portable structure ensures convenience and ease of use, allowing users to receive therapy at any time and place. The device also provides consistent and controlled stimulation, supporting effective neurological outcomes.
The main product categories of portable transcranial stimulation devices include transcranial direct current stimulation (tDCS) devices, transcranial magnetic stimulation (TMS) devices, and others. Transcranial direct current stimulation (tDCS) devices are portable tools that deliver low-intensity electrical currents to specific brain regions to alter neuronal activity for therapeutic or cognitive improvement. These devices are available through both online and offline distribution channels and are applied in areas such as depression, anxiety, pain management, cognitive enhancement, and others. They are used by various end users, including hospitals and clinics, home care environments, research institutes, and others.
Tariffs have raised costs for electronic control units, electrodes, and magnetic components used in portable transcranial stimulation devices, particularly impacting tDCS and portable TMS products manufactured in Asia-Pacific regions. These cost pressures have slowed adoption in Europe and North America, but they are also encouraging domestic production, simplified device designs, and innovation in wearable and home-use neuromodulation systems.
The portable transcranial stimulation device market research report is one of a series of new reports from The Business Research Company that provides portable transcranial stimulation device market statistics, including portable transcranial stimulation device industry global market size, regional shares, competitors with a portable transcranial stimulation device market share, detailed portable transcranial stimulation device market segments, market trends and opportunities, and any further data you may need to thrive in the portable transcranial stimulation device industry. This portable transcranial stimulation device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The portable transcranial stimulation device market size has grown rapidly in recent years. It will grow from $1.37 billion in 2025 to $1.51 billion in 2026 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to growth in neurological disorders, advances in neurostimulation technology, rising mental health awareness, demand for non-invasive therapies, increased clinical research.
The portable transcranial stimulation device market size is expected to see strong growth in the next few years. It will grow to $2.18 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to AI-guided stimulation optimization, expansion of home neurotherapy, cognitive performance enhancement demand, integration with digital therapeutics, growth in aging population. Major trends in the forecast period include non-invasive brain stimulation, home-use neuromodulation devices, portable cognitive enhancement tools, personalized stimulation protocols, wearable neurotherapy devices.
The increasing prevalence of neurological and psychiatric disorders is anticipated to drive the growth of the portable transcranial stimulation device market in the coming years. Neurological and psychiatric disorders affect the brain and nervous system, resulting in alterations in thinking, emotions, or behavior. The increase in these disorders is largely associated with chronic stress, which disrupts brain chemistry and neural function, reducing mental resilience and heightening vulnerability to such conditions. Portable transcranial stimulation devices influence brain activity through low-intensity electrical currents directed at specific regions, enhancing neural connectivity and function to help relieve symptoms of neurological and psychiatric disorders in a non-invasive and accessible way. For example, in October 2023, the World Federation of Neurology, a UK-based association of national neurological societies, reported that over 40% of the global population currently experiences some form of neurological condition, with this figure expected to nearly double by 2050. Therefore, the growing prevalence of neurological and psychiatric disorders is fueling the expansion of the portable transcranial stimulation device market.
Leading companies in the portable transcranial stimulation device market are emphasizing the development of advanced products such as transcranial direct current stimulation (tDCS) devices to offer non-invasive and user-friendly solutions for both home and clinical use. Transcranial direct current stimulation (tDCS) devices are non-invasive instruments that deliver low-intensity electrical currents to targeted brain regions to regulate neuronal activity, enhance cognitive functions, and support the management of neurological and psychiatric conditions. For instance, in October 2023, Sooma Oy, a Finland-based medical device manufacturer, introduced Sooma Duo, a portable tDCS-based brain stimulation device designed to provide clinician-prescribed neuromodulation therapies for conditions such as depression and chronic pain. The device features remote clinician monitoring, preset electrode positioning, and automatic resistance control, improving treatment adherence, therapeutic results, and accessibility of brain stimulation therapies in home and clinical settings.
In March 2025, Lindus Health, a UK-based contract research organization, collaborated with Sooma Medical to conduct a pivotal phase 3 clinical trial evaluating Sooma's wearable transcranial direct current stimulation (tDCS) cap, Sooma 2GEN, as a home-based treatment for major depressive disorder (MDD). This partnership aims to produce comprehensive safety and efficacy data in real-world remote conditions, expedite regulatory approval, and promote the broader commercialization of Sooma's portable brain stimulation platform. Sooma Medical is a Finland-based manufacturer of portable transcranial stimulation devices.
Major companies operating in the portable transcranial stimulation device market are Neuroelectrics Barcelona S.L.U., Flow Neuroscience AB, Soterix Medical Inc., Sooma Medical Inc., Fisher Wallace Laboratories Inc., Caputron LLC, PlatoScience Inc., TheBrainDriver GmbH, Neurosoft Ltd., G.Tec Medical Engineering, Ybrain Co. Ltd., Remed Co. Ltd., Nexalin Technology Inc., NeuroSigma Inc., Mind Alive Inc., Ionclinics GmbH, NeuroEM Therapeutics Inc., Salvia BioElectronics B.V., RPW Technology LLC, Neurocare Group AG
North America was the largest region in the portable transcranial stimulation device market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the portable transcranial stimulation device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the portable transcranial stimulation device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The portable transcranial stimulation device market consists of sales of stimulation headbands, wearable stimulation caps, handheld stimulators, electrode patches, rechargeable battery packs, stimulation kits, and electrode gels. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Portable Transcranial Stimulation Device Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses portable transcranial stimulation device market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for portable transcranial stimulation device ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The portable transcranial stimulation device market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.